Patent settlement with Orbicular allows generic YUPELRI launch on April 23, 2039

Theravance Biopharma, Inc.

Settlement resolves Hatch-Waxman litigation with Orbicular over YUPELRI (revefenacin).
Orbicular granted royalty-free license to market generic revefenacin on or after April 23, 2039.
Litigation continues against four other ANDA filers: Cipla, Eugia, Lupin, and Mankind Pharma.
Settlement subject to review by U.S. DOJ and FTC as required by law.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.